Preliminary study of early response to neoadjuvant chemotherapy after the first cycle in breast cancer: comparison of 1H magnetic resonance spectroscopy with diffusion magnetic resonance imaging

被引:32
作者
Tozaki, Mitsuhiro [1 ]
Oyama, Yu [2 ]
Fukuma, Eisuke [1 ]
机构
[1] Kameda Med Ctr, Breast Ctr, Kamogawa 2968602, Japan
[2] Kameda Med Ctr, Dept Clin Oncol, Chiba, Japan
关键词
Breast cancer; Proton MRS; Diffusion-weighted imaging; Neoadjuvant chemotherapy; Therapeutic response; PROTON MR SPECTROSCOPY; PREOPERATIVE CHEMOTHERAPY; CONTRAST AGENTS; CHOLINE PEAK; SPECIFICITY; MAMMOGRAPHY; MALIGNANCY; GUIDELINES; GADOLINIUM; DIAGNOSIS;
D O I
10.1007/s11604-009-0391-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose. The aim of this study was to assess the efficacy of single-voxel H-1 magnetic resonance spectroscopy (MRS) at 1.5 T to evaluate early responses to neoadjuvant chemotherapy after the first treatment in breast cancer patients and to compare it to measurements of apparent diffusion coefficient ( ADC) values derived from diffusion-weighted magnetic resonance imaging (MRI). Materials and methods. Nine patients with breast cancer who were scheduled to receive neoadjuvant chemotherapy were recruited. MR examination after the first cycle was scheduled for a few days before the administration of the second dose. Results. Two patients were excluded from the study because their regimen was changed after the first cycle. MRS before chemotherapy demonstrated the presence of choline (Cho) at 3.22-3.23 ppm in six cases and at 3.27 ppm in one case. Diffusion-weighted MRI before chemotherapy demonstrated a localized high-signal lesion in all cases. The change of the integral value of Cho after the first cycle of chemotherapy showed a positive correlation with the change in lesion size (r = 0.91, P = 0.01), whereas no correlation was observed between the change of ADC values after the first cycle and the change in lesion size (r = 0.45, P = 0.32). Conclusion. MRS after the first cycle may be more sensitive to diffusion-weighted MRI to predict the pathological response.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 33 条
[1]  
Aboagye EO, 1999, CANCER RES, V59, P80
[2]   Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: Preliminary study [J].
Bartella, L ;
Morris, EA ;
Dershaw, DD ;
Liberman, L ;
Thakur, SB ;
Moskowitz, C ;
Guido, J ;
Huang, W .
RADIOLOGY, 2006, 239 (03) :686-692
[3]   SPATIAL LOCALIZATION IN NMR-SPECTROSCOPY INVIVO [J].
BOTTOMLEY, PA .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1987, 508 :333-348
[4]   Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18 [J].
Fisher, B ;
Brown, A ;
Mamounas, E ;
Wieand, S ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Fisher, ER ;
Wickerham, DL ;
Wolmark, N ;
DeCillis, A ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) :2483-2493
[5]   Effect of preoperative chemotherapy on the outcome of women with operable breast cancer [J].
Fisher, B ;
Bryant, J ;
Wolmark, N ;
Mamounas, E ;
Brown, A ;
Fisher, ER ;
Wickerham, DL ;
Begovic, M ;
DeCillis, A ;
Robidoux, A ;
Margolese, RG ;
Cruz, AB ;
Hoehn, JL ;
Lees, AW ;
Dimitrov, NV ;
Bear, HD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2672-2685
[6]  
GALONS JP, 1999, NEOPLASIA, V1, P133
[7]   Meeting highlights: International consensus panel on the treatment of primary breast cancer [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Senn, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3817-3827
[8]   Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging [J].
Guo, Y ;
Cai, YQ ;
Cai, ZL ;
Gao, YG ;
An, NY ;
Ma, L ;
Mahankali, S ;
Gao, JH .
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2002, 16 (02) :172-178
[9]   Detection of breast malignancy: Diagnostic MR protocol for improved specificity [J].
Huang, W ;
Fisher, PR ;
Dulaimy, K ;
Tudorica, LA ;
O'Hea, B ;
Button, TM .
RADIOLOGY, 2004, 232 (02) :585-591
[10]  
IARC, 2003, WHO CLASS TUM PATH G